Home » Singapore Issues Guidance for Abridged Evaluation of New Drug Applications
Singapore Issues Guidance for Abridged Evaluation of New Drug Applications
October 14, 2010
Sponsors of new drug applications (NDAs) for life-saving drugs that have the potential to fill unmet medical needs may request a priority review if the submission is under an abridged evaluation route, according to a draft guidance issued by Singapore’s Health Sciences Agency (HSA).
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor